

Reference:	FOI.13720.24
Subject:	Biologic medicines in gastroenterology
Date of Request:	2 February 2024

Requested:

How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Etrasimod
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Vedolizumab

Response:

Hywel Dda University Health Board (UHB) provides, within the table below, the number of UHB patients treated by the Gastroenterology Department, with the listed biologic medicines, during the period 1 November 2023 to 31 January 2024.

Medicine	Number
Adalimumab – Humira	*
Adalimumab Biosimilar	118
Etrasimod	0
Filgotinib	6
Golimumab	0
Infliximab – Remicade	*
Infliximab Biosimilar	66
Mirikizumab	0
Ozanimod	*
Risankizumab	0
Tofacitinib	*
Upadacitinib	14
Ustekinumab	131
Vedolizumab	96

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore

withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.